Grifols therapeutics LLC- ocular surface immunoglobulin in the management of vesicant agents injury
Ended Definitive Contract Awarded Last action
- Contract number
- 75A50124C00050
- Awardee
-
Grifols Therapeutics LLC UEI UFQ3A7GKJ5C7
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $613,200
Award facts
- Opportunity
-
- BAA20SOL1000002 Solicitation number
- Contract value 100% obligated
- $613,200.00 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Durham, NC 27709, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $613,200 |
About this award
Grifols Therapeutics LLC, a Durham, North Carolina-based pharmaceutical and biopharmaceutical manufacturer, was awarded a $613.2K definitive contract by the Office of the Assistant Secretary for Preparedness and Response on September 27, 2024. The contract, which carries no small business set-aside designation, supports research and development of ocular surface immunoglobulin products intended to treat injuries caused by vesicant agents. Work will be performed at the contractor's facility in Research Triangle Park, North Carolina, with a completion deadline of December 15, 2025. The firm fixed price contract reflects the government's investment in medical countermeasures and therapeutic solutions for chemical injury management.
The award aligns with ASPR's mission to enhance national preparedness and response capabilities for health security threats, including chemical, biological, radiological, and nuclear incidents. Grifols Therapeutics has established itself as a reliable federal supplier of specialized immunological products, with a track record of delivering mission-critical pharmaceutical treatments to agencies including the Department of Veterans Affairs. This contract represents the company's expertise in immunoglobulin therapies and its capacity to develop innovative medical solutions addressing emergency preparedness and response requirements.
Quick answers
Who was awarded contract 75A50124C00050?
75A50124C00050 was awarded to Grifols Therapeutics LLC by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 27, 2024.
How much is contract 75A50124C00050 worth?
The government has obligated $613,200 on 75A50124C00050.
Was contract 75A50124C00050 competed?
The extent of competition for 75A50124C00050 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award